# Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

> **NCT06483386** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 109 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine

## Key facts

- **NCT ID:** NCT06483386
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 109 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483386, "Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06483386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*